Intas Pharma finalized its acquisition of UDENYCA, a biosimilar to Neulasta, from Coherus Life Sciences for $558 million in December 2024. ...

Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherap...

Fulphila, co-developed by Biocon Biologics and Mylan, was the first biosimilar pegfilgrastim to be approved in the US and was launched in J...

Fulphila, co-developed by Biocon Biologics and Mylan, was the first biosimilar pegfilgrastim to be approved in the US and was launched in J...

Neulasta had US sales of $4.2 billion for the 12 months to March, according to IQVIA.

S&P BSE Sensex was trading 44.17 points lower at 34,967.72 with HDFC Bank as top gainer.

The product has recently been introduced under the brand Accofil and has already won two prestigious tenders, in Netherlands and the UK.

Venus Remedies aims to launch its major products in global markets with an eye on more than doubling revenues to Rs 1,000 cr by 2016-17.

Venus Remedies shares rallied nearly 10% in morning trade, after the company received patent from Mexico for its novel antibiotic Potentox.

Granted by the Mexican Institute of Industrial Property, the patent protects the composition of Potentox, the company said.

Venus Remedies has got US patent for Potentox, used for pneumonia other infections and is looking at increasing presence in the $ 12 bn ant...

Pharmaceutical company Venus Remedies has received regulatory approval for marketing its second research product in Ukraine.